Myriad Genetics MYGN Prenatal — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Myriad Genetics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's prenatal — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Myriad Genetics's prenatal — revenue?
- Myriad Genetics (MYGN) reported prenatal — revenue of $44.9M in Q4 2025.
- How has Myriad Genetics's prenatal — revenue changed year-over-year?
- Myriad Genetics's prenatal — revenue decreased by 0.0% year-over-year, from $44.9M to $44.9M.
- What is the long-term trend for Myriad Genetics's prenatal — revenue?
- Over 2 years (2023 to 2025), Myriad Genetics's prenatal — revenue has grown at a 11.0% compound annual growth rate (CAGR), from $151.3M to $186.3M.
- What does prenatal — revenue mean?
- Represents the total gross income generated specifically from the sale and delivery of molecular diagnostic prenatal testing services. This metric tracks the commercial performance of the prenatal product line, reflecting market adoption and pricing power within the reproductive health diagnostics sector. It serves as a key indicator of the company's ability to capture share in the prenatal screening market.